TY - JOUR
T1 - An investigation into the potential of SarAr for Use in 64Cu radioimmunotherapy
AU - Di Bartolo, Nadine
AU - Smith, Suzanne V.
AU - Hetherington, Eric
AU - Sargeson, Alan
PY - 2009
Y1 - 2009
N2 - The B72.3 monoclonal antibody was radiolabelled with 123I, and with 111In and 64Cu, using DTPA and SarAr, respectively. Their biodistribution in tumour-bearing nude mice was used to calculate the dosimetry of their respective therapeutic analogue, using 131I, 90Y, 67Cu, and 64Cu. Two dosimetry models were used: one using the classical approach and a second model that takes into consideration the chemical stability of the radiolabelling methods employed and the biological clearance of each radioimmunoconjugate. Results clearly show that the 64Cu-SarAr-B72.3 could be used as a therapeutic agent and, theoretically, be at least as effective as any of the other therapeutic radionuclides currently studied, such as 131I, 90Y, and 67Cu.
AB - The B72.3 monoclonal antibody was radiolabelled with 123I, and with 111In and 64Cu, using DTPA and SarAr, respectively. Their biodistribution in tumour-bearing nude mice was used to calculate the dosimetry of their respective therapeutic analogue, using 131I, 90Y, 67Cu, and 64Cu. Two dosimetry models were used: one using the classical approach and a second model that takes into consideration the chemical stability of the radiolabelling methods employed and the biological clearance of each radioimmunoconjugate. Results clearly show that the 64Cu-SarAr-B72.3 could be used as a therapeutic agent and, theoretically, be at least as effective as any of the other therapeutic radionuclides currently studied, such as 131I, 90Y, and 67Cu.
UR - http://www.scopus.com/inward/record.url?scp=70350089840&partnerID=8YFLogxK
U2 - 10.1071/CH09369
DO - 10.1071/CH09369
M3 - Article
SN - 0004-9425
VL - 62
SP - 1261
EP - 1270
JO - Australian Journal of Chemistry
JF - Australian Journal of Chemistry
IS - 10
ER -